Zobrazeno 41 - 50
of 214
pro vyhledávání: '"Eudocia Q. Lee"'
Autor:
Viktor A. Adalsteinsson, Jackson Stocking, Megha Subramanian, Alex K. Shalek, Samuel Markson, Ivanna Bihun, Joana L. Mora, Andrew W. Navia, Scott L. Carter, Priscilla K. Brastianos, Daniel P. Cahill, Nancy Wang, Eudocia Q. Lee, Christopher Alvarez-Breckenridge, Kellie E. Kolb, Sanjay M. Prakadan, Marc H. Wadsworth, Denisse Rotem, Jeffrey W. Miller, Ryan J. Sullivan, Robert H. Klein, Michael White, Benjamin M. Kuter, Alexander Kaplan, Ugonma Chukwueke, Albert E. Kim, Mia Bertalan, Brian A. Shaw, Naema Nayyar
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Leptomeningeal disease (LMD) is a devastating complication of solid tumor malignancies, with dire prognosis and no effective systemic treatment options. Over the past decade, the incidence of LMD has steadily increased due to therapeutics that have e
Autor:
Giorgio Gaglia, Ziming Du, Louis B. Nabors, Yang Dai, Ishwar N. Kohale, Ilya Korsunsky, Brian M. Alexander, Jann N. Sarkaria, Eudocia Q. Lee, Patrick Y. Wen, Michael S. Regan, Sankha S. Basu, Soumya Raychaudhuri, Elizabeth C. Randall, Keith L. Ligon, Bianca-Maria Marin, Forest M. White, Ann C. Mladek, Sandro Santagata, Nathalie Y. R. Agar, Stuart A. Grossman, Danielle M. Burgenske, Jeffrey G. Supko, Jeffrey N. Agar, Amanda R Clark, Sylwia A. Stopka, Walid M. Abdelmoula, Begoña Gimenez-Cassina Lopez
Publikováno v:
Neuro Oncol
Background Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping d
Autor:
Eudocia Q. Lee
Publikováno v:
Current Treatment Options in Oncology
Opinion statement Clinical trials play a critical role in discovering new treatments, but the path to regulatory approval can be cumbersome and time consuming. Efforts to increase the efficiency and interpretability of clinical trials within the neur
Autor:
Wenya Linda Bi, Erik H. Knelson, Eudocia Q. Lee, Alexandra M Giantini Larsen, Luis Fandino, Hassan Y. Dawood, Ian F. Dunn, Saksham Gupta, Ayal A. Aizer, Timothy R. Smith
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
IntroductionBrain metastases are the most common brain tumors in adults, whose management remains nuanced. Improved understanding of risk factors for surgical complications and mortality may guide treatment decisions.MethodsA nationwide, multicenter
Autor:
Chitkala Kalidas, W. K. Alfred Yung, Andrew B. Lassman, John de Groot, David Arons, Joseph C. Kvedar, Mustafa Khasraw, Susan M. Chang, Clair Meehan, Lee H. Schwamm, Mary Welch, Jeffrey A. Bacha, Erik Bloomquist, Solmaz Sahebjam, Wendy Selig, Patrick Y. Wen, Evanthia Galanis, Vinay K. Puduvalli, Amy Barone, Gelareh Zadeh, Islam Hassan, Eudocia Q. Lee, Sharon Tamir
Publikováno v:
Neuro-Oncology
On July 24, 2020, a workshop sponsored by the National Brain Tumor Society was held on innovating brain tumor clinical trials based on lessons learned from the COVID-19 experience. Various stakeholders from the brain tumor community participated incl
Autor:
Mark Muzi, Paul A Jerabek, David A. Reardon, Shiliang Huang, Peter T. Fox, Geoffrey D. Clarke, Patrick Y. Wen, Hyewon Hyun, Andrew Brenner, Kathleen M. Schmainda, Joel E. Michalek, Eudocia Q. Lee, John Floyd
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Tumoral hypoxia correlates with worse outcomes in glioblastoma (GBM). While bevacizumab is routinely used to treat recurrent GBM, it may exacerbate hypoxia. Evofosfamide is a hypoxia-targeting prodrug being tested for recurrent GBM. To characterize r
Autor:
Jennifer Bruno, L. Burt Nabors, Shyam K. Tanguturi, Howard Colman, Mary Welch, Brittany Fisher-Longden, William Pisano, Eudocia Q. Lee, Mehdi Touat, Tracy T. Batchelor, Geffrey Fell, Jan Drappatz, Emily Lapinskas, Rifaquat Rahman, David A. Reardon, Manmeet Ahluwalia, Wenya Linda Bi, Isabel Arrillaga-Romany, Ugonma Chukwueke, Thomas Kaley, Jaroslaw T. Hepel, David Schiff, Christine McCluskey, Heinrich Elinzano, Lakshmi Nayak, E. Antonio Chiocca, Evanthia Galanis, Christine Lu-Emerson, Daphne A. Haas-Kogan, Brian M. Alexander, David Meredith, J Ricardo McFaline-Figueroa, Lorenzo Trippa, Mikael L. Rinne, Daniel N. Cagney, Rameen Beroukhim, Maria Lavallee, Ayal A. Aizer, Keith L. Ligon, Omar Arnaout, Lisa Doherty, Sarah Gaffey, Andrew B. Lassman, Shanna Dowling, Patrick Y. Wen
Publikováno v:
Neuro Oncol
BACKGROUND The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial with Bayesian adaptive randomization and deep genomic profiling to more efficiently test experimental agents in newly diagnosed gl
Autor:
Brian M. Alexander, G.C. Youssef, Patrick Y. Wen, David A. Reardon, Ugonma Chukwueke, J.R. McFaline-Figueroa, Diana D. Shi, Eudocia Q. Lee, Wenya Bi, Shyam K. Tanguturi, S. Whorral, Daphne A. Haas-Kogan, Lakshmi Nayak, Rifaquat Rahman, Daniel N. Cagney, M. Allen, Rameen Beroukhim, Ayal A. Aizer, Keith L. Ligon, Mary Jane Lim-Fat
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e598-e599
PURPOSE/OBJECTIVE(S) While glioblastoma (GBM) is known to have increased incidence in males, recent work has identified possible sex-specific molecular differences that could be associated with improved clinical outcomes for female GBM patients. We e
Autor:
David A. Reardon, Jennifer Stefanik, Christine McCluskey, Dan G. Duda, Alona Muzikansky, Andrew D. Norden, Tracy T. Batchelor, John G. Kuhn, Rakesh K. Jain, Patrick Y. Wen, Eudocia Q. Lee, Debra LaFrankie, Sarah C. Gaffey, Elizabeth R. Gerstner, Lisa Doherty, Katrina H. Smith, Lakshmi Nayak, Trupti Vardam
Publikováno v:
Clinical Cancer Research. 24:4643-4649
Purpose: Although antiangiogenic therapy for high-grade glioma (HGG) is promising, responses are not durable. Correlative clinical studies suggest that the SDF-1α/CXCR4 axis may mediate resistance to VEGFR inhibition. Preclinical data have demonstra
Autor:
Sydney Whorral, Wenya Linda Bi, Lakshmi Nayak, David Meredith, Marie Allen, Mehdi Touat, Bryan Iorgulescu, Tracy T. Batchelor, Rifaquat Rahman, Jayne Vogelzang, William Pisano, Eudocia Q. Lee, E. Antonio Chiocca, Gilbert Youssef, Mary Jane Lim-Fat, David A. Reardon, Eleanor Woodward, Ugonma Chukwueke, Patrick Y. Wen, Jose Mcfaline-Figueroa, Keith L. Ligon, Sandro Santagata, Rameen Beroukhim
Publikováno v:
Neuro Oncol
BACKGROUND Comprehensive next generation sequencing (NGS) is available through many academic institutions and commercial entities, and is incorporated in practice guidelines for glioblastoma (GBM). We retrospective evaluated the practice patterns and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffa97ef5cdf5df4268af1121c87664d6
https://europepmc.org/articles/PMC7650887/
https://europepmc.org/articles/PMC7650887/